Clovis Oncology (NASDAQ:CLVS) slips 4% premarket on light volume on the heels of a downgrade to Neutral with a fair value target of $7 (23% upside) (from $13) at BofA citing expected competition from AstraZeneca's (NYSE:AZN) Lynparza in prostate cancer.
Quant rating is Very Bearish while the Sell Side rating is Outperform.
https://seekingalpha.com/news/3490979-clovis-4-percent-premarket-bofa-downgrade
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.